Key facts
- This page summarizes Mark Chin's Form 4 filing for Iterum Therapeutics plc (ITRM).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 15 Jun 2023, 17:00.
Mark Chin - 15 Jun 2023 Form 4 Insider Report for Iterum Therapeutics plc (ITRM)
- Reporting relationship
- Director
- Issuer ticker
- ITRM
- Reported as of
- 15 Jun 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 15 Jun 2023, 17:00:10 UTC
- Prior SEC filing
- 09 Jun 2023
- Next SEC filing
- 23 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark Chin
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Mark Chin filed Form 4 for Iterum Therapeutics plc (ITRM) on 15 Jun 2023.
Change
- Previous filing in this sequence was filed on 09 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ITRM
transaction
Ordinary Shares
Options Exercise
- Transaction value
- $0
- Shares
- +15,853
- Change %
- +646%
- Price
- $0.000000
- Shares after
- 18,306
- Date
- 15 Jun 2023
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ITRM
transaction
Derivative
Restricted Share Units
Options Exercise
- Transaction value
- $0
- Shares
- -15,853
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 15 Jun 2023
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 15,853
- Exercise price
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs.
Footnote F2
On August 17, 2022 the Issuer effected a 1 for 15 reverse share split (the "Reverse Share Split"). The number of ordinary shares reported in this Form 4 have been adjusted to reflect the Reverse Share Split.
Footnote F3
On June 15, 2022, the reporting person was granted an award of 15,853 RSUs, which vested in full on June 15, 2023.